Log In Sign up
The largest database of trusted experimental protocols

On targetplus control pool non targeting pool

Manufactured by Horizon Discovery
Visit Supplier

The ON-TARGETplus Control pool and Non-targeting pool are laboratory reagents designed for use in gene silencing experiments. The Control pool contains a non-targeting siRNA sequence, while the Non-targeting pool contains a pool of non-targeting siRNA sequences. These products are intended to serve as controls to assess the specificity of gene silencing in cell-based assays.

Automatically generated - may contain errors

Lab products found in correlation

Lipofectamine rnaimax reagent protocol, by Thermo Fisher Scientific (1 mentions) Lipofectamine rnaimax reagent, by Thermo Fisher Scientific (1 mentions) Sigenome smartpool, by Horizon Discovery (1 mentions) Lipofectamine rnaimax, by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

ON-TARGETplus Non-targeting Control Pool ON-TARGETplus Non-targeting Control Pool siRNA ON-TARGETplus Non-targeting Control Pool (D-001810-10) ON-TARGETplus Non-targeting Pool ON-TARGETplus control pool Non-targeting control pool Non-targeting Pool ON-TARGETplus

3 protocols using on targetplus control pool non targeting pool

1

GRHL2 Knockdown Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Knockdown of GRHL2 was undertaken using ON-TARGETplus SMARTpool Human GRHL2, Dharmacon (#L-014515-02-0050) and Lipofectamine® RNAiMAX Reagent Protocol (Thermo) according to the manufacturer’s protocol. Control samples were prepared following the same method using ON-TARGETplus Control pool Non-targeting pool, Dharmacon (#D-001810-10-50) in place of siGRHL2.
Holding A.N., Giorgi F.M., Donnelly A., Cullen A.E., Nagarajan S., Selth L.A, & Markowetz F. (2019). VULCAN integrates ChIP-seq with patient-derived co-expression networks to identify GRHL2 as a key co-regulator of ERa at enhancers in breast cancer. Genome Biology, 20, 91.
+ Open protocol
+ Expand
2

siRNA-Mediated Knockdown of BAP1

Check if the same lab product or an alternative is used in the 5 most similar protocols
BAP1 was knocked-down using specific small interfering RNA (siRNA) oligonucleotides (ON-TARGET plus Human BAP1 siRNA; Dharmacon, Lafayette, CO, USA). ON-TARGET plus Control Pool Non-Targeting Pool (Dharmacon) were used as the negative control. For transfection, the cationic lipid-mediated transfection method, using Lipofectamine RNAiMAX Reagent (Invitrogen), was adopted according to the manufacturer’s instructions. The sequences of the siRNA used in this study are shown in S2 Table.
Hirosawa T., Ishida M., Ishii K., Kanehara K., Kudo K., Ohnuma S., Kamei T., Motoi F., Naitoh T., Selaru F.M, & Unno M. (2018). Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer. PLoS ONE, 13(11), e0206643.
+ Open protocol
+ Expand
3

OMA1 and YME1L Knockdown in NRK Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
50 nM OMA1 siRNA (siGENOME SMARTpool, Dharmacon); target sequences: GUAGGACUCUCAAGAACAA; UUGAAUAGCGUGACCGAUA; GACAUACGCACUUGGGAAA; GGUCAAUGCCUUCGUGCUU and 50 nM YME1L siRNA (Ambion); sequence (5′ ➔ 3′): GUCAUGCUAUUAUUGC AUAtt (sense) and UAUGCAAUAAUAGCAUGACca (antisense) were used to knockdown OMA1 and YME1L in NRK cells, respectively. Scrambled siRNA (ON-TARGETplus Control Pool, Non-Targeting Pool, Dharmacon); target sequences: UGGUUUACAUGUCGACUAA, UGGUUUACAUGUUGUGUGA, UGGUUUACAUGUUUUCUGA; UGGUUUACAUGUUUUCCUA was used as a control. SiRNA was diluted (50 nM final concentration) in OptiMEM 1X (Life Technologies) with Lipofectamine RNAiMAX (Invitrogen) accordingly to manufacturer's instructions. At 50% cell confluency, NRK cells were transfected with the siRNA solution, and lysed 24 h later using RIPA lysis buffer. Successful knockdown of OMA1 and YME1L was confirmed via protein immunoblotting.
Tobacyk J., Parajuli N., Shrum S., Crow J.P, & MacMillan-Crow L.A. (2019). The first direct activity assay for the mitochondrial protease OMA1. Mitochondrion, 46, 1-5.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!